Ranibizumab
Prijeđi na navigaciju
Prijeđi na pretragu
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 347396-82-1 |
| ATC kod | S01LA04 |
| DrugBank | DB01270 |
| UNII | ZL1R02VT79 
|
| KEGG[1] | D05697
|
| ChEMBL[2] | CHEMBL1201825
|
| Hemijski podaci | |
| Formula | C2158H3282N562O681S12 |
| Mol. masa | 48000 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 9 dana |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravitrealno |
Ranibizumab (prodajno ime Lucentis) fragment je monoklonalnog antitela (Fab) izveden iz istog mišjeg antitela kao i bevacizumab (Avastin). On je znatno manji od roditeljskog molekula i bio je podvrgnut procesu maturacije afiniteta da bi se pojačalo vezivanje za VEGF-A. On je inhibitor angiogeneze koji je odobren za lečenje "vlažnog" tipa starostne makularne degeneracije (AMD, ARMD), i uobičajeme forme starosnog gubitka vida.[3][4][4][5][6][7][8][9]
Reference[uredi | uredi kod]
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CZ8&Part=Chain Arhivirano 2008-12-07 na Wayback Machine-u
- ↑ 4,0 4,1 Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6. PMID 18046235
- ↑ Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33. PMID 15671306
- ↑ Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179-82. PMID 18054637
- ↑ Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61. PMID 18035187
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
